The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center

PURPOSES: Pasireotide is the first medical therapy officially approved for adult patients with Cushing’s disease (CD) experiencing failure of pituitary surgery or not candidates for surgery. The current study aimed at investigating pasireotide effects on clinical picture and metabolic profile in pat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Endocrinol Invest
Autori principali: Simeoli, C., Ferrigno, R., De Martino, M. C., Iacuaniello, D., Papa, F., Angellotti, D., Pivonello, C., Patalano, R., Negri, M., Colao, A., Pivonello, R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6952330/
https://ncbi.nlm.nih.gov/pubmed/31313243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40618-019-01077-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi